Based on this analysis, all 3 gepants are not cost-effective compared with usual care for the treatment of acute migraine.
Lorenzo Villa Zapata, PhD
Advertisement
Articles by Lorenzo Villa Zapata, PhD
The authors explore the economic impact and accessibility challenges of new Alzheimer disease drugs under the Inflation Reduction Act, with emphasis on Medicare, pricing, and health care equity.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Flatiron’s AI-Driven Telescope Makes Data Access More User-Friendly
2
Social Factors May Match, Outpace Genetic Risk in Disease Prediction
3
First Generic of Priftin Approved by FDA for Tuberculosis Treatment and Prevention
4
Long-Term, Consistent Resistance Training Linked to Substantially Lower Type 2 Diabetes Risk
5